An Exploration Strategy Improves the Diversity of de novo Ligands Using Deep Reinforcement Learning – A Case for the Adenosine A2A Receptor

<p>Over the last five years deep learning has progressed tremendously in both image recognition and natural language processing. Now it is increasingly applied to other data rich fields. In drug discovery, recurrent neural networks (RNNs) have been shown to be an effective method to generate novel chemical structures in the form of SMILES. However, ligands generated by current methods used to provide relatively little diversity and do not fully cover the whole chemical space occupied by known ligands. Here, we propose a new method (DrugEx) to discover <i>de novo</i> drug-like molecules. DrugEx is an RNN model (generator) trained through a special exploration strategy integrated into reinforcement learning. As a case study we applied our method to design ligands against the adenosine A<sub>2A</sub> receptor. From ChEMBL data, a machine learning model (predictor) was created to predict whether generated molecules are active or not. Based on this predictor as the reward function, the generator was trained by reinforcement learning without any further data. We then compared the performance of our method with two previously published methods, REINVENT and ORGANIC. We found that candidate molecules our model designed that were predicted to be active, had a larger chemical diversity, and better covered the chemical space of known ligands compared to the state-of-the-art.</p>